This Ichnos Glenmark drug promises to BEAT cancer, affordably. Can it challenge Big Pharma?
Synopsis
The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such drugs is expected to touch USD30 billion by the end of the decade. Although these are early days, can it take on the likes of J&J, Gilead, and Sanofi?
San Diego’s crisp December air and vast beaches call for a relaxing Californian vacation. But besides tourists lazing around, the city last month had some serious business to attend. Over 30,000 researchers and medical experts gathered at the Pacific coast city for a meeting of the American Society of Haematology (ASH).The prestigious group of renowned experts in blood disorders annually scans and deliberates on over 5,000 research abstracts for
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Refer & Earn
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
